A phase 3 study of chemotherapy 1 pembrolizumab versus chemotherapy 1 placebo as first-line therapy for patients with advanced esophageal or esophagogastric junction (E/EGJ) cancer: KEYNOTE-590-Trial in progress


Kato K., Shah M., Enzinger P., Bennouna J., Shen L., Adenis A., ...Daha Fazla

ESMO 20th World Congress on Gastrointestinal Cancer, Barcelona, İspanya, 20 - 23 Haziran 2018, cilt.29 identifier

  • Cilt numarası: 29
  • Basıldığı Şehir: Barcelona
  • Basıldığı Ülke: İspanya